Private Advisor Group’s Sage Therapeutics SAGE Stock Holding History

Private Advisor Group’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,950	Closed	-$123K	–	3076
2020 Q2	$123K	Buy	+2,950	New	+$107K	﹤0.01%	1588

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Private Advisor Group's SAGE Position: Q3 2020 in Review

Private Advisor Group sold out of Sage Therapeutics (SAGE) in Q3 2020, closing a stake of 2,950 shares — an estimated $123K sold.

Private Advisor Group first reported a position in SAGE in Q2 2020 and held it in 1 quarter. The position peaked at $123K in Q2 2020. 231 funds tracked by Wall St. Rank hold SAGE as of Q3 2020.

Private Advisor Group reported no remaining Sage Therapeutics position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 2,950 Sage Therapeutics shares in Q3 2020, an estimated $123K.
Private Advisor Group first reported a position in Sage Therapeutics in Q2 2020 and held it in 1 quarter.
Private Advisor Group's Sage Therapeutics position peaked at $123K in Q2 2020.
231 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.